使用雷帕鸣需要注意什么？

It is mainly used to treat patients aged 13 or above who have received kidney transplants and prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids. Currently on the market, Rapamide produced by Biocon in India is favored by the majority of patients. Its pharmaceutical ingredients and usage methods are the same as the original drug.

Biocon India is a global biopharmaceutical company that believes everyone has the right to affordable, quality medicines. From assembly line to production, from drug development to drug delivery, we bring differentiated, high-quality and affordable medical products to communities around the world.

You need to pay attention to the following when using Rapamin produced by Biocon India:

1. Anaphylaxis/hypersensitivity reaction: Anaphylaxis, angioedema, exfoliative dermatitis and hypersensitivity vasculitis have been reported. Patients with the above situations need to contact their doctor in time.

2. Infection: Immunosuppression may also increase the risk of infection, including activation of latent viral infections (including BK virus-related nephropathy), fatal infections, and sepsis. Pneumocystis jiroveci pneumonia (PCP) should be prophylactically treated 1 year after transplantation, and cytomegalovirus (CMV) should be prophylactic 3 months after transplantation.

3. Hyperlipidemia: May increase blood lipids (cholesterol and triglycerides). Monitoring is required during treatment, and patients with hyperlipidemia should use it with caution.

4. Interstitial lung disease: Cases (some fatal) of interstitial lung disease (such as pneumonia, organizing pneumonia, bronchiolitis obliterans, pulmonary fibrosis, etc.) have been observed; may be related to pulmonary hypertension (including pulmonary hypertension). Relief may occur by reducing the dose or discontinuing treatment.

It is a prescription drug. Patients must strictly follow the doctor's instructions during treatment and actively cooperate with the treatment.

Recommended related hot articles: /newsDetail/89055.html